MicroRNA in Human Acute Kidney Injury: A Systematic Review Protocol

Adrianna Douvris¹, Dylan Burger¹,², Rosendo A. Rodriguez³, Edward G. Clark¹, Jose Viñas¹, Manoj M. Lalu²,⁴, Risa Shorr³, and Kevin D. Burns¹,²

Abstract

Background: Acute kidney injury (AKI) is a common complication of hospitalization with high morbidity and mortality for which no effective treatments exist and for which current diagnostic tools have limitations for earlier identification. MicroRNAs (miRNAs) are small non-coding RNAs that have been implicated in the pathogenesis of AKI, and some miRNAs have shown promise as therapeutic tools in animal models of AKI. However, less is known about the role of miRNAs in human AKI.

Objective: To evaluate the role of miRNAs in human subjects with AKI.

Design: Systematic review and meta-analysis

Measurements: Quantification of miRNA levels from human blood, urine, or kidney biopsy samples, and measures of renal function as defined in the study protocol.

Methods: A comprehensive search strategy for Ovid MEDLINE All, Embase, Web of Science, and CENTRAL will be developed to identify investigational studies that evaluated the relationship between miRNA levels and human AKI. Primary outcomes will include measurements of kidney function and miRNA levels. Study screening, review and data extraction will be performed independently by 2 reviewers. Study quality and certainty of evidence will be assessed with validated tools. A narrative synthesis will be included and the possibility for meta-analysis will be assessed according to characteristics of clinical and statistical heterogeneity between studies.

Limitations: These include (1) lack of randomized trials of miRNAs for the prevention or treatment of human AKI, (2) quality of included studies, and (3) sources of clinical and statistical heterogeneity that may affect strength and reproducibility of results.

Conclusion: Previous studies of miRNAs in different animal models of AKI have generated strong interest on their use for the prevention and treatment of human AKI. This systematic review will characterize the most promising miRNAs for human research and will identify methodological constraints from miRNA research in human AKI to help inform the design of future studies.

Systematic review registration: PROSPERO CRD42020201253

Abrégé

Contexte: L’insuffisance rénale aiguë (IRA) est une complication fréquente des hospitalisations avec morbidité et mortalité élevées. Il n’existe aucun traitement efficace contre l’IRA et les outils diagnostiques actuels qui permettent son dépistage précocé comportent des limites. Les microARN (miARN) sont de petits ARN non codants ayant été impliqués dans la pathogenèse de l’IRA; certains d’entre eux se sont révélés prometteurs comme outils thérapeutiques dans les modèles animaux de l’IRA. Le rôle des miARN dans l’IRA chez l’humain est cependant moins connu.

Objectif: Évaluer le rôle des miARN chez les sujets humains atteints d’IRA.

Type d’étude: Examen systématique et méta-analyse

Mesures: La quantification des taux de miARN chez l’humain à partir d’échantillons de sang, d’urine ou de biopsie rénale, et mesure de la fonction rénale telle que définie dans le protocole de l’étude.

Méthodologie: Une stratégie de recherche exhaustive des bases de données Ovid MEDLINE All, Embase, Web of Science et CENTRAL sera élaborée afin de répertorier les études expérimentales ayant évalué la relation entre les taux de miARN et l’IRA chez l’humain. Les principaux critères d’évaluation comprendront la mesure de la fonction rénale et des taux de miARN. Deux examinateurs procéderont de façon indépendante à la sélection des études, à leur examen et à l’extraction des données. La qualité des études et la robustesse des données seront évaluées à l’aide d’outils validés. Une synthèse descriptive
Background

Acute kidney injury (AKI) refers to a rapid decline in kidney function. Acute kidney injury affects up to 20% of hospitalized patients particularly in those admitted to intensive care units (ICU).1 Patients who develop AKI have an increased risk of death1 and are more likely to have long term adverse outcomes if they recovered from AKI. In a meta-analysis of 82 studies with 2 million hospitalized adults followed for minimum 1 year, AKI was associated with a nearly 2-fold increased risk of death, a 3-fold increased risk of new or progressive chronic kidney disease (CKD), and a 4-fold increased risk of kidney failure compared to patients without AKI.2 The incremental cost of AKI in Canada is estimated to exceed CAN$200 million per year, and greater severity AKI is associated with incremental increases in both hospital length of stay and costs.3 Despite the health and economic burden of AKI, no effective interventions currently exist for treatment,4 preventative measures are limited,5 and current diagnostic tools including serum creatinine and urine output have major limitations for earlier identification.6

AKI can be caused by different mechanisms, including ischemia-reperfusion injury (IRI), sepsis, and nephrotoxins. At the cellular level, proximal tubular and endothelial cell injury involve pathways in inflammation, apoptosis, angiogenesis, and fibrosis.7 MicroRNAs (miRNAs) are small non-coding RNAs, well conserved across species, that regulate gene expression at the post-transcriptional level by binding the 3′-untranslated region (UTR) of messenger RNA (mRNA), thereby inhibiting mRNA translation and promoting mRNA degradation.8 Thus far, more than 1500 miRNAs have been identified in humans and have been found to be involved in many biological processes including cell cycle regulation, apoptosis, hypoxia, metabolism, immunity, and oncogenesis.7 Over the last 10 years, there has been an expanding effort to evaluate the role of miRNAs in AKI. This is reflected by the increasing annual number of publications on this topic over this time period in PubMed: from 4 publications in 2010, to an average of 50-60 publications annually over the last 5 years.

Several miRNAs have been studied in animal models of AKI—the most frequent of which is miR-21—for their expression patterns, mechanisms of action and therapeutic potential.9 For instance, Song et al evaluated the effect of miR-21 knockdown on AKI using in vitro hypoxia/re-oxygenation and in vivo mouse IRI models.10 These knockdown studies suggest that miR-21 protects against ischemic AKI. miR-21 knockdown intensified ischemia-induced renal epithelial cell injury by (1) enhanced apoptosis through the phosphatase and tensin homolog (PTEN)/Akt/mammalian target of rapamycin (mTOR)/hypoxia-inducible factor (HIF) pathways and (2) increased inflammation by promoting dendritic cell maturation.10

Pre-clinical research is an important step for the translation of basic science to human studies, and a systematic review of miRNAs as therapy for pre-clinical models of AKI

Keywords

acute kidney injury, systematic review, human, microRNA, biomarker

Received December 22, 2020. Accepted for publication March 12, 2021.
is underway. Although miRNAs are showing promise as therapies in pre-clinical AKI models, much less is known about their potential as a therapy to prevent or treat AKI in humans. Furthermore, pre-clinical studies have not readily translated to human application and study design flaws are a contributing factor. For example, many studies of IRI-AKI are conducted in male animals. However, animal experimental models have shown that female sex confers protection against IRI-AKI, an observation that has also been noted from observational studies and meta-analysis in humans.

Currently, no clinical trials on the therapeutic use of miRNA in human AKI have been registered (clinicaltrials.gov, https://www.isrctn.com/), but several miRNAs have been evaluated as biomarkers of AKI and other kidney diseases. In cardiac surgery and critically ill patients, small studies that measured urinary or plasma levels of miRNAs as a prognostic marker of AKI have reported conflicting results and this highlights the complexity of miRNA pathways. One such example is miR-21, whose levels have been shown to be increased in the urine and plasma of critically ill and cardiac surgery patients with AKI, yet another study of cardiac surgery patients found that lower pre-operative plasma miR-21 levels conferred an increased risk of developing cardiac surgery-associated AKI. This systematic review will evaluate many aspects of miRNAs related to human AKI, including an improved understanding of the pathophysiology related to different AKI causes, and will identify methodological limitations, sources of heterogeneity and outcome measure differences, which will help inform the planning and design of clinical trials.

### Methods

#### Study Design

This systematic review will be reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements, and the Cochrane Handbook for Systematic Reviews of Interventions will be used as best-practice guidance. The study protocol was written in accordance with PRISMA for protocols (PRISMA-P) and is registered with the International Prospective Register of Systematic Reviews (PROSPERO CRD42020201253). A populated PRISMA-P checklist is provided in supplementary file 1.

#### Objectives

The primary aim is to evaluate the role of miRNAs in human AKI. The secondary aims will be to evaluate the association between miRNAs and renal outcomes including AKI severity, the incidence of dialysis-requiring AKI, renal recovery, and in-hospital mortality. The relationship between timing of miRNA measures in AKI and clinical outcomes, and the effect of sex on miRNA expression in AKI will be evaluated if possible.

#### Types of Studies

Observational and interventional studies (randomized and non-randomized) evaluating miRNAs in human AKI that meet the inclusion criteria below will be included. Narrative reviews, editorials, and case reports will be excluded.

#### Population

Studies of human subjects (adult and pediatric populations) with both dialysis-requiring and non-dialysis-requiring AKI will be included. AKI will be defined broadly using RIFLE and AKIN definitions outlined in the KDIGO clinical practice guidelines for AKI. All AKI causes will be included (ie, etiology), but if there are sufficient number of studies, subgroup analyses will be conducted to determine any differences in the etiology of AKI. Studies of patients with end-stage kidney disease treated with kidney replacement therapy (maintenance dialysis) will be excluded.

Studies involving non-human animal and cell culture models will be excluded.

#### Exposure

The exposure of interest is AKI. Studies will characterize the relationship between the presence of AKI, AKI severity and etiology, and miRNA levels.

#### Comparator(s)

Studies will be comparing miRNA levels in patients with AKI to those without AKI. In the event there is no comparator group, studies may compare miRNA levels with differing severity of AKI.

#### Confounders

These include any variables that can influence miRNA levels. As miRNAs affect a range of biological processes and their expression is dysregulated in many diseases, confounders include AKI cause and CKD, diabetes mellitus, infection/sepsis, cancer, and medications (ie anticoagulants and anti-cancer agents). Age will also be explored as a confounding factor.

#### Outcomes

(a) **Primary outcome:** miRNA levels from blood, urine, or kidney tissue in association with AKI. miRNA quantification methods may include but are not limited to quantitative PCR, microarray, or quantification using fluorescence in situ hybridization.

(b) **Secondary outcomes:** (1) Measurement of renal function by serum Cr, BUN or urea, or urine volume; (2) biomarkers of AKI (ie neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1) or others); and kidney structural changes by kidney biopsy for histological analyses if available; (3) measures of association between miRNA levels and other outcomes of interest: (i) severity of AKI, (ii) dialysis-requiring AKI, and (iii) complete or
partial renal recovery (broad criteria due to lack of uniform definition32 includes serum Cr < 1.5× baseline, or, no longer requiring renal replacement therapy, or, serum Cr decreases but does not return to <1.5× baseline), and (iv) in-hospital mortality. 

(c) **Exploratory outcomes:** (i) the association between sex and miRNA levels in AKI, (ii) between miRNA level and AKI cause, and (iii) timing of miRNA measurement and clinical outcomes.

**Search Strategy**

We performed an initial search using PubMed for prior systematic reviews on this topic. We also searched PROSPERO to identify currently registered systematic reviews. We did not identify any prior or ongoing systematic review.

We will implement a comprehensive search strategy in collaboration with a research librarian (provided in supplementary file 2). The search will include terms related to acute kidney injury, miRNA, and extracellular vesicles (which may contain miRNA as cargo).

We will search the following databases from years 1947 to present:

- Ovid MEDLINE All
- Embase
- CENTRAL (Cochrane Central Register of Controlled Trials)
- Web of Science

The search will be supplemented by manually scanning the reference list of all included studies for additional material. Editorials, review articles, case reports, patent applications, and studies involving only animal or in-vitro experiments will be excluded. Abstracts from the last 5 years from the American Society of Nephrology scientific meetings will be reviewed. A search of clinicaltrials.gov for any contemporary or previous protocols will be conducted to verify eligible studies.

**Study Selection**

Titles and abstracts initially identified from our search will be exported to Covidence for independent screening by at least 2 investigators. Duplicate citations will be removed.

The following requirements must be met for an article to be considered for full text review:

- Original study (observational or interventional) of human AKI with miRNA expression measures. We will exclude non-original research (ie review or editorials), and pre-clinical studies.
- Possible causes of AKI include but are not limited to (1) pre-renal, hepatorenal, or cardio-renal syndrome; (2) acute tubular necrosis; (3) major surgery (ie cardiac, vascular, intra-abdominal); (4) shock; (5) sepsis; (6) nephrotoxins; (7) acute obstruction; (8) acute interstitial nephritis; (9) acute glomerulonephritis; (10) malignancy-associated AKI and (11) AKI in renal transplant recipients including delayed graft function and acute rejection. Studies of patients with end-stage kidney disease treated with kidney replacement therapy (maintenance dialysis) will be excluded.
- Studies in English and French languages will be included.
- Studies that do not specifically address miRNA or kidney function will be excluded.

The 2 reviewers will also document the primary reason for article exclusion after full text review. Any discrepancies between included and excluded studies between the 2 independent reviewers will be discussed for a consensus decision. If a consensus cannot be reached, a third reviewer will provide an independent opinion. We will calculate the kappa statistic for inter-reviewer reliability.

**Data Extraction**

A data extraction form will be created and piloted prior to duplicate data extraction by 2 independent reviewers. The data extracted will include the following:

- **Study characteristics:** authors, journal information, publication year, geographic location, in-patient setting (ward, ICU, post-cardiac surgery, transplant), study design, type of publication (abstract or full manuscript).
- **Population characteristics:** Age, sex, ethnicity, comorbidities, AKI setting (ie ICU, post-cardiac surgery, etc), admission diagnosis, AKI cause.
- **Type of exposure and comparator:**
  - Type of kidney insult responsible for AKI if applicable to the study (ie cardiac surgery, sepsis, nephrotoxin) and timing of AKI if available.
  - Control group characteristics
  - Duration of follow-up.

- **Outcomes:**
  - **Primary outcome:** miRNA characteristics: variant, type of sample (blood, urine, kidney tissue), timing of measurement relative to AKI, method of miRNA measurement including assay and instrument. Normalization methods and measurement units for miRNA expression will be identified.
  - **Secondary and exploratory outcomes:** (i) measures of renal function and markers of AKI as described above; (ii) AKI severity, incidence of dialysis-requiring AKI, in-hospital mortality, renal recovery;
(iii) comparison of miRNA levels with presence of AKI, renal outcomes, and sex; (iv) relationship between miRNA and AKI cause; and (v) timing of miRNA measurement and clinical outcomes.

If information is missing from a study, attempts will be made to contact the study authors. The data will be exported from Covidence for data analysis.

**Risk of Bias and Quality Assessment**

Two independent reviewers will assess the included studies for potential bias and quality. Non-randomized studies will be evaluated for risk of bias using the Newcastle-Ottawa Scale (NOS), which evaluates study group selection, comparability, and outcomes. If randomized studies meeting inclusion criteria are identified, risk of bias will be evaluated with the Cochrane Handbook Risk of Bias Assessment Tool. Any disagreements will be resolved by discussion, and, if not possible, then a third reviewer.

**Data Synthesis and Analysis**

The decision to perform a meta-analysis on the primary outcome will depend on the assessment of statistical and clinical heterogeneity. Assessment of clinical heterogeneity between studies will be based on miRNA variant, sample type (blood, urine, kidney biopsy), miRNA normalization methods, AKI cause, and timing of measurement relative to AKI if available. We will assess statistical heterogeneity using the $I^2$ statistic. If statistical heterogeneity between studies is high ($I^2 > 50\%$ and deemed to represent considerable heterogeneity), then data will be reported descriptively for the outcomes of interest. In these cases, we will provide a narrative synthesis of included studies using the Synthesis Without Meta-analysis (SwiM) reporting guideline as a framework. If clinical and statistical heterogeneity are acceptable, studies with similar outcomes measures and miRNAs will be pooled to calculate pooled weight effect estimates using the inverse variance method, and data will be modeled according to the DerSimonian-Laird Method (random effects model).

If sufficient studies are eligible, we will report on likely confounders of miRNA expression, including cause of AKI, underlying comorbidities (ie CKD, diabetes mellitus, cancer), medications, and acute medical conditions (ie type of surgery, infection, shock, acute coronary syndrome). We will assess the quality of control for confounders by reporting whether studies: (1) had balanced groups, (2) matched subjects for the confounders, and (3) adjusted for the confounders in their statistical analyses. Where possible, we will perform sub-group analyses listed in the following.

**Subgroup Analysis**

If data are available from included studies, subgroup analyses will include the following:

(a) Population characteristics:
   a. Pediatric vs adult population
   b. Male vs female sex

(b) Exposures:
   a. AKI cause
   b. Severity of AKI

(c) Outcomes:
   a. Timing of miRNA measurement relative to AKI: categorized as (1) prior to AKI onset, (2) early AKI (within 48 hours of injury), or (3) late (after 48 hours)
   b. Sample type (blood, urine, or tissue)
   c. Requirement for renal replacement therapy (yes/no)
   d. Renal recovery (yes/no)
   e. In-hospital mortality (yes/no)

Assessment of reporting biases will be performed on the primary outcome by constructing a funnel plot if an adequate number of studies is identified.

Data analysis will be performed using RevMan 5.3.

**Assessing the Quality of Evidence**

The quality of evidence for the primary outcome will be assessed as “very low” to “high” in accordance to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Workgroup. Limitations of included studies will also be identified with suggestions for improvement where possible.

**Discussion**

AKI occurs frequently in hospitalized patients and is associated with increased morbidity and mortality. There is an important need for tools for early detection of AKI, and the development of novel therapies for its prevention and treatment. Pre-clinical miRNA studies in AKI have shown promise as potential AKI markers and therapies. Those studies have uncovered plausible biological mechanisms implicating several miRNAs in the pathogenesis of AKI. More than 50 different miRNAs are differentially expressed in AKI, but their significance in human AKI is unclear. In addition, translating pre-clinical AKI research to clinical practice has proven to be challenging due to pre-clinical methodological issues that are beyond the scope of this review, and important differences between experimental AKI models and human AKI. For instance, rodents and other mammals lack modeling for common medical comorbidities such as CKD, diabetes mellitus, or hypertension which impact AKI prognosis. There are sex-specific differences in AKI susceptibility, thus most pre-clinical studies are conducted in male animals. Of note, gender may have effects independently of biological sex; however, this is unlikely to be reported. Pre-clinical models are also not truly representative of AKI in humans which is often multifactorial in the setting of systemic...
illness. Another consideration is the timing of intervention in human AKI: with the exception of specific circumstances (ie planned cardiac surgery), the onset of AKI is often unknown or identified late.

A systematic review of miRNAs in human AKI will identify the miRNAs selected for study in humans thus far, the reason for their selection (ie biological mechanism, pre-clinical results) and may uncover other miRNAs that have not yet been studied in pre-clinical models, creating new research opportunities for scientists. Our systematic review of miRNAs in experimental AKI models will serve to facilitate the comparison of miRNAs in pre-clinical versus human AKI. Further, a systematic review of miRNAs in human AKI will address the heterogeneity and controversy among studies of miRNA in AKI by identifying the directionality and magnitude of miRNA associations with AKI. This information can be used to determine if pre-clinical studies support the direction of effects seen in human AKI, and, if quantitative analysis of effect size is possible, can be helpful to calculate an estimated sample size in future clinical trials. It will also identify important limitations from existing studies that could be used by researchers to improve future clinical trial design. These include methodological limitations, sources of heterogeneity, and confounders that could impact accuracy of results, and outcome measures. Overall, this information will inform researchers and clinicians on better planning further well-designed studies for both AKI diagnosis and treatment.

There are limitations to this planned systematic review. We do not expect to identify human clinical trials of miRNA delivery systems for the prevention or treatment of AKI. Our data will come from descriptive clinical studies which will not provide mechanistic information on their own without pre-clinical experimental models. The timing of miRNA measures relative to AKI may not be possible to control in some clinical settings which may affect the primary outcome, but timing will be considered in the analysis. Finally, small sample sizes and study design with respect to case and control cohorts may also affect the strength and reproducibility of results.

The field of miRNA therapeutics is beginning to evolve from pre-clinical studies to phase I/II clinical trials in other disciplines. In Oncology, the first such phase I trial used a miR-34 mimic (MRX34) with an intravenous nanoparticle liposomal delivery system for 85 adult patients with refractory advanced solid tumors. Although the study was able to show miR-34 delivery to tumors and dose-dependent target gene modulation, it was stopped early due to serious immune-related adverse effects. In the treatment of hepatitis C infection, a retrospective follow up analysis of a phase 2a multicentre trial found that the locked nucleic acid antisense inhibitor of miR-122miraviren had a sustained virological response in 58% (7/12) of trial participants and no significant adverse effects over a 35-month follow-up period. Given miRNA therapeutics are being studied in clinical trial settings for other illnesses, this could be a promising direction for the prevention and treatment of AKI.

Conclusions

A systematic review and meta-analysis of the role of miRNAs in human AKI will be conducted. This study will identify and characterize the most promising miRNAs for further AKI research and methodological limitations from current miRNA research in human AKI that will help improve the design of future clinical and experimental studies in this area.

List of Abbreviations

AKI, acute kidney injury; AKIN, acute kidney injury network; BUN, blood urea nitrogen; CKD, chronic kidney disease; Cr, creatinine; GRADE, grading of recommendations assessment, development and evaluation; ICU, intensive care unit; IRI, ischemia reperfusion injury; KDIGO, kidney disease improving global outcomes; mRNA, messenger RNA; miRNA, microRNA; NOS, Newcastle Ottawa Scale; RIFLE, risk, injury, failure, loss, end-stage kidney disease; UTR, untranslated region.

Ethics Approval and Consent to Participate

Not applicable.

Consent for Publication

All authors have given their consent for publication.

Availability of Data and Materials

All data are available upon request.

Author Contributions

KDB conceptualized the study. AD drafted the initial manuscript. RS, AD, and KDB drafted the proposed search strategy. RAR, MML, and EC provided important input into the study design and data analysis components. AD, DB, RAR, EC, MML, JV, and KDB all contributed to manuscript review and editing and approved the final version. KDB is the guarantor of the manuscript.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study is supported by funds from the Canadian Institutes of Health Research (CIHR; grant number HDK-388364) to the corresponding author (KDB). CIHR had no role in the development of this study. MML is supported by The Ottawa Hospital Anesthesia Alternate Funds Association and holds a University of Ottawa Junior Research Chair in Innovative Translational Research.
ORCID iDs
Adrianna Douvris https://orcid.org/0000-0001-9578-9785
Rosendo A. Rodriguez https://orcid.org/0000-0002-6039-9274
Edward G. Clark https://orcid.org/0000-0002-6767-1197

Supplemental Material
Supplemental material for this article is available online.

References
1. Wang HE, Muntner P, Chertow GM, Warnock DG. Acute kidney injury and mortality in hospitalized patients. *Am J Nephrol*. 2012;35:349-355.
2. See EJ, Jayasinghe K, Glassford N, et al. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. *Kidney Int*. 2019;95(1):160-172.
3. Collister D, Pannu N, Ye F, et al. Health care costs associated with AKI. *Clin J Am Soc Nephrol*. 2018;13(2):1733-1743.
4. Jo SK, Rosner MH, Okusa MD. Pharmacological treatment of acute kidney injury: why drugs haven’t worked and what is on the horizon. *Clin J Am Soc Nephrol*. 2007;2:356-365.
5. KDIGO clinical practice guidelines for acute kidney injury. *Kidney Int Suppl*. 2012;2:19-36.
6. Romagnoli S, Ricci Z, Ronco C. Perioperative acute kidney injury: prevention, early recognition, and supportive measures. *Nephron*. 2018;140(2):105-110.
7. Jones TF, Bekele S, O’Dwyer MJ, Prowle JR. MicroRNAs in acute kidney injury. *Nephron*. 2018;140(2):124-128.
8. Fan P-C, Chen C-C, Chen Y-C, Chang Y-S, Chu P-H. MicroRNAs in acute kidney injury. *Hum Genom*. 2016;10:29.
9. Brandenburger T, Somozzo AS, Devaux Y, Lorenzen JM. Noncoding RNAs in acute kidney injury. *Kidney Int*. 2018;94:870-881.
10. Song N, Zhang T, Xu X, et al. MiR-21 protects against ischemia/reperfusion-induced acute kidney injury by preventing epithelial cell apoptosis and inhibiting dendritic cell maturation. *Front Physiol*. 2018;9:790.
11. Zankar S, Rodriguez RA, Vinas JL, Burns KD. The therapeutic effects of microRNAs in preclinical studies of acute kidney injury: a systematic review protocol. *Syst Rev*. 2019;8:235.
12. Brandenburger T, Lorenzen JM. Diagnostic and therapeutic potential of microRNAs in acute kidney injury. *Front Pharmacol*. 2020;11:657.
13. de Caeester M, Humphreys BD, Liu KD, et al. Bridging translation by improving preclinical study design in AKI. *J Am Soc Nephrol*. 2015;26(12):2905-2916.
14. Viñas JL, Porter CJ, Douvris A, et al. Sex diversity in proximal tubule and endothelial gene expression in mice with ischemic acute kidney injury. *Clinical Science*. 2020;134:1887-1909.
15. Tanaka R, Tsutsui H, Okhita M, Takaoka M, Yukiura T, Matsumura Y. Sex differences in ischemia/reperfusion-induced acute kidney injury are dependent on the renal sympathetic nervous system. *Eur J Pharmacol*. 2013;714:397-404.
16. Kher A, Meldrum KK, Wang M, Tsai BM, Pitcher JM, Meldrum DR. Cellular and molecular mechanisms of sex differences in renal ischemia–reperfusion injury. *Cardiovasc Res*. 2005;67:594-603.
17. Kang KP, Lee JE, Lee AS, et al. Effect of gender differences on the regulation of renal ischemia–reperfusion-induced inflammation in mice. *Mol Med Rep*. 2014;9(6):2061-2068.
18. Neugarten J, Golestanl H, Kolhe NV. Sex differences in acute kidney injury requiring dialysis. *BMC Nephrology*. 2018;19:131.
19. Neugarten J, Golestanl H. Female sex reduces the risk of hospital-associated acute kidney injury: a meta-analysis. *BMC Nephrology*. 2018;19:314.
20. Saikumar J, Hoffmann D, Kim T-M, et al. Expression, circulation, and excretion profile of MicroRNA-21, -155, and -18a following acute kidney injury. *Toxicol Sci*. 2012;129(2):256-267.
21. Ramachandran K, Saikumar J, Bijol V, et al. Human miRNome profiling identifies MicroRNAs differentially present in the urine after kidney injury. *Clin Chem*. 2013;59(12):1742-1752.
22. Du J, Cao X, Zou L, et al. MicroRNA-21 and risk of severe acute kidney injury and poor outcomes after adult cardiac surgery. *PLoS ONE*. 2013;8:e63390.
23. Gaede L, Liebetrau C, Blumenstein J, et al. Plasma microRNA-21 for the early prediction of acute kidney injury in patients undergoing major cardiac surgery. *Nephrol Dial Transplant*. 2016;31(5):760-766.
24. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Plos Medicine*. 2009;6:e1000097.
25. Higgins J, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews of Interventions Version 6.1*. 2nd ed. Chichester, England: John Wiley & Sons; 2020.
26. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. *Circ Res*. 2010;107:810-817.
27. Benz F, Roy S, Trautwein C, Roderburg C, Luedde T. Circulating MicroRNAs as Biomarkers for Sepsis. *Int J Mol Sci*. 2016;17:78.
28. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. *Nat Rev Drug Discov*. 2017;16(3):203-222.
29. To KK, Tong CW, Wu M, Cho WC. MicroRNAs in the prognosis and therapy of colorectal cancer: from bench to bedside. *World J Gastroenterol*. 2018;24:2949-2973.
30. Barraclough JY, Joan M, Joglekar MV, Hardikar AA, Patel S. MicroRNAs as prognostic markers in acute coronary syndrome patients—A systematic review. *Cells*. 2019;8:1572.
31. Kashani K, Cheungpasitporn W, Ronco C. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption. *Clin Chem Lab Med*. 2017;55:1074-1089.
32. Kellum JA. How can we define recovery after acute kidney injury? Considerations from epidemiology and clinical trial design. *Nephron Clin Pract*. 2014;127(1-4):81-88.
33. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Published 2012. Accessed April 7, 2021.
34. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. *BMJ*. 2011;343:d5928.
35. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine*. 2002;21:1539-1558.
36. Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. *BMJ*. 2020;368:16890.
37. Deeks J, Higgins J, Altman D. Chapter 10: analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. *Cochrane Handbook for Systematic Reviews of Interventions*. Version 6.1. Cochrane. www.training.cochrane.org/handbook. Published 2020. Accessed April 7, 2021.
38. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336:924-926.
39. Pelletier R, Khan NA, Cox J, et al. Sex versus gender-related characteristics: which predicts outcome after acute coronary syndrome in the young? *J Am Coll Cardiol*. 2016;67:127-135.
40. Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. *Invest New Drugs*. 2017;35(2):180-188.
41. Hong DS, Kang Y-K, Borad M, et al. Phase I study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. *Br J Cancer*. 2020;122:1630-1637.
42. van der Ree MH, van der Meer AJ, de Bruijne J, et al. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. *Antiviral Res*. 2014;111:53-59.